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accepted June 13,eart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and
treatment of HF. The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are
not well delineated. A systematic search of the electronic databases and the World Health Organization website was
undertaken for HF in LA. LA countries have reduced gross income and lower total expenditure on health per capita.
LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of
raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and
Chagas’ disease (C’D) are higher in LA. Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3%
to 37%), C’D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%),
and alcohol related (from 1.1% to 8%). The prognosis of C’D HF is worse than for other etiologies. Chronic HF is the
cause of death in 6.3% of cases. Decompensated HF is the main cause of cardiovascular hospitalization. The
prevalence of systolic HF varies from 64% to 69%. LA is under the awful paradox of having the HF risk factors and HF
epidemiology of developed countries with the added factors of SH, C’D, and rheumatic fever. Overall, in the scenario
of lower total expenditure on health per capita and lower gross national income per capita, new strategies are
essential for prevention and treatment of HF in LA. (J Am Coll Cardiol 2013;62:949–58) ª 2013 by the American
College of Cardiology FoundationThe knowledge of risk factors of heart failure (HF) in Latin
America (LA) is essential because apart from the prevalence
of risk factors comparable to developed countries in certain
areas, the epidemiology of HF can also be inﬂuenced by risk
factors that are more frequent in LA. In fact, a review about
HF in LA is of immediate interest. Also, the review of new
LA HF data, including HF risk factors obtained from the
World Health Organization (WHO), recent registry data
from LA countries and institutions, epidemiological studies,
analyses of LA HF populations selected for recent HF trials,
LA expenditure in health and gross income, and new
advances in the cumulative knowledge of neglected diseases
in LA, could have a strong impact on planning future health
policies for HF in LA. Therefore, the objective of this review
is to offer an HF LA update as a valuable resource for
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2013.professionals, and many others who seek the best available
data on HF.Systematic Review Methodology
The online MEDLINE PubMed database (National Center
for Biotechnology Information, U.S. National Library of
Medicine, Bethesda, Maryland) and other electronic
bibliographic databases (e.g., ClinicalTrials.gov, Cochrane
Library, Elsevier/ScienceDirect, SciELO, LILACS) were
searched for data literature from LA in September and
October 2012. The search strategy used the MeSH terms
“heart failure,” “chronic heart failure,” “decompensated heart
failure,” “acute heart failure,” “Chagas’ disease,” “chagasic
heart failure,” “diastolic heart failure,” and “systolic heart
failure.” All titles and abstracts of the articles were evaluated.
After exclusion based on the title and abstract, full articles
were evaluated, and articles meeting the inclusion criteria
were identiﬁed. Relevant articles with information about
epidemiology were examined and thus reviewed. Data from
the WHO were also obtained.Risk Factors for HF in LA
Socioeconomic deprivation is a powerful independent
predictor of HF development and adverse outcomes (1). The
reduced gross income per capita of LA countries (US$8,555)
in comparison with Canada (US$38,370) and the United
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950States (US$47,310) is evidence for
a lower economic status in LA and
increased HF risk (2). The lower
total expenditure on health per
capita, and lower total expenditure
on health as a percentage of gross
national income per capita, indi-
cate limited access to primary or
secondary care of diseases leading
to HF, or to therapies that have
been shown to be effective in
treating HF. In reference to access
to health care, 2009 U.S. data
from the WHO show the expen-
diture on health care as a per-centage of the gross domestic product and as per capita costs is
17.9% and US$8,364, respectively, whereas in LA, Brazil,
Argentina, Chile, and Mexico, the values were 7.2% and
US$632, 9% and $943, 9.5% and $1,387, 8.2% and $1.172,
and 6.5% and $846, respectively (2).
Variability in the high prevalence of HF risk factors can
be observed among LA countries inWHOdata (Figs. 1 to 5).
The WHO and CARMELA (Cardiovascular Risk Factor
Multiple Evaluation in Latin America) study data suggest
that some countries in LA may have HF risk factorsised Blood Glucose Levels in
oth Sexes, Age >25 Years
d Health Organization data (2008) (2).comparable to developed countries (3). In the CARMELA
study, the prevalence of systemic arterial hypertension (SH)
was 18% (9% to 29%), hypercholesterolemia 14% (6% to
20%), diabetes 7% (4% to 9%), metabolic syndrome 20%
(14% to 27%), obesity 23% (18% to 27%), and smoking
30% (22% to 45%). Also, data showing that 40% to 49%
of populations in some LA countries are Afro-Americans
or mulatto is evidence for higher-risk HF in LA because
black ethnicity was associated with a high risk of incidental
HF (4). An increment in the elderly population is expected in
Brazil and LA in the next decades, with implications for
a higher HF burden (5). The inﬂuence of age and sex on HF
differs among different countries (Table 1). In Argentina,
a review of 5 registries involving 2,974 patients between 1992
and 2004 showed that the mean age of HF subjects was 65 to
70 years old, with 40% female (6), although outpatients
studies in Argentina showed a large predominance of men
(82% to 79%) (Table 1) (7). In Brazil, HF patients seem to be
younger (53 to 73 years old), and at least 1 study showed
female predominance (58%) (8–10). In Chile, the mean age
in an in-hospital cohort was 69 years old, with a slight
predominance of men (59%) (11).
In summary, data from the WHO and the CARMELA
study, corroborated by data from the recent LASO study,
indicate that LA is currently experiencing a large-scale
epidemic of HF risk factors (12). This could be attribut-
able to an epidemiological transition with changes inFigure 2
Prevalence of Raised Systemic Blood Pressure Levels
in a Population of Both Sexes, Age >25 Years
Prevalence is according to the World Health Organization data (2008) (2).
Figure 4
Tobacco Use Prevalence in a Population of Both
Sexes, Age >15 Years
Prevalence is according to the World Health Organization data (2009) (2).
Figure 3
Obesity Prevalence in a Population of Both Sexes,
Age >20 Years
Prevalence according to the World Health Organization data (2008) (2).
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951lifestyle, increased life expectancy, urbanization, physical
inactivity, and high-caloric and high-fat diets (13). An
increment in HF risk factors in LA countries could cause
deep concern. The increase might not be closely followed by
more access to preventive and treatment strategies for HF,
given LA’s limited expenditure on health. The threat to LA
countries comes from the paradox of having HF risk factors
similar to developed countries, but without the HF
preventive and treatment policies of developed countries.Decompensated HF
In 2007, data from the Brazilian Ministry of Health showed
that 39.4% of hospital admissions were related to decom-
pensated HF (DHF). This proportion was 70% in the
over-60-year age group (14). DHF was the single most
frequent cause of hospitalization in the elderly population in
Brazil (15). Hospital discharges with a ﬁnal diagnosis of
HF increased 164% from 1979 (total 377,000) to 2000
(999,000). Tables 1 and 2 show the etiology, age, type of HF
(systolic HF or HF with preserved left ventricular ejection
fraction [HFPEF]), prognosis, and days of hospitalization
for DHF in LA (8,16–23).
In comparison with other countries in the ADHERE-I
(Acute Decompensated Heart Failure National Registry–
International) study, LA countries had a longer average
length of stay when compared with Asian-Paciﬁc countriesFigure 5 Life Expectancy of Both Sexes at Birth
Expectancy is according to the World Health Organization data (2).
Table 1 Etiology of HF in LA According to Studies in Selected Populations
First Author (Ref. #) Country Year N Mean Age (yrs)
Etiology
IDC C’D Isch SH Valv Alco Perip Myo EMF Toxi
Outpatient
Freitas et al. (16) Brazil 2005 1,220 45 37 20 17 14 5 4 2 1 <1% <1%
Bocchi et al. (4) Brazil 2008 350 50 and 52 10–17 21–16 22–28 22–18 3 8–4 NA d d NA
Mendez et al. (31) Mexico 2007 72 61 44 d 47 d d d d d d d
Silva et al. (38) Brazil 2007 96 52 28.2 8.6 28.2 20.6 6.5 2.1 3.2 d d d
Ferrante et al. (37) Argentina 2005 1,518 65 NA NA 44.4 NA d NA NA d d d
Doval et al. (7) Argentina 1994 516 50 and 52 19.5–23.0 10.5–8.1 38.3–39.6 NA d NA NA d d d
DHF
Mangini et al. (17) Brazil 2008 212 60 8 15 30 21 15 NA NA NA NA NA
Latado et al. (18) Brazil 2006 299 69 3 9.7 49.2 25.8 11.7 d d 0.7 d d
Tavares et al. (25) Brazil 2004 203 50 and 52 NA NA 62–68 NA NA NA NA NA NA NA
Fairman et al. (19) Argentina 2009 736 74 NA 4 21 76 20 NA NA NA NA NA
Perna et al. (6) Argentina 1992–2004 2,974 65–70 1.3–13.8 1.3–8.4 27–38 18.2–32.3 16–22 1.0–5.4 d d d d
Castro et al. (11) Chile 2004 372 69 7.4 d 31.6 35 14.8 2.2 NA NA NA NA
Bocchi et al. (20) Brazil 2008 182 55 NA 21 34 NA NA NA NA NA NA NA
Barretto et al. (8) Brazil 1998 903 53 25.8 6.2 32.6 7 22 NA NA NA NA NA
Rohde et al. (9) Brazil 2005 143 73 NA 0.6 39 25 10 NA NA NA NA NA
McSwain et al. (28) Antigua-Barbuda 1999 293 69 5 d 33 41 12 2 NA NA NA NA
Thierer et al. (21) Argentina 2002 400 68 5 4.3 28 21.8 17 NA NA NA NA NA
Rizzo et al. (22) Argentina 2004 615 70 3.7 8.4 27.4 18.2 16.4 NA NA NA NA NA
Thierer et al. (23) Argentina 2006 2,201 68 9.3 6 40.5 23.7 12 d d d d d
Values are %.
Alco ¼ alcohol etiology; C’D ¼ Chagas’ disease; DHF ¼ decompensated heart failure in hospitalized patients; EMF ¼ endomyocardial ﬁbrosis; HF¼ heart failure; IDC ¼ idiopathic dilated cardiomyopathy; Myo ¼myocarditis; Perip ¼ peripartum cardiomyopathy; SH ¼ systemic
arterial hypertension; Toxi ¼ toxicity by drugs (for example, chemotherapy for cancer); Valv ¼ valvular etiology.
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Table 2 Prevalence of Systolic HF and HFPEF and Mortality in LA
HF Type
First Author (Ref. #) Year N Systolic HFPEF In-Hospital Mortality Late Mortality Days of Hospitalization Hospitalization
Outpatient
Freitas at al. (16) 2005 1,220 100 d d 34 (26 m) d d
Bocchi et al. (4) 2008 350 80.0 and 81.6 20.0 and 19.4 d 17.5 (12 m) and
48–60 (60 m)
d d
Mendez et al. (31) 2007 72 63 37 d 12 for SHF
(6 m)
d d
Silva et al. (38) 2007 96 100 d d d d d
Ferrante et al. (37) 2005 1,518 79.4 20.6 d 15.3–16.1
(16 m)
d 34.3 and 39.1
(16 m)
Doval et al. (7) 1994 516 100 d d 24.5–32.5
(12 m)
d d
DHF
West et al. (24) 2011 151y and 33z d 45.7* 8.5y and 2.9z d 10y and 7z d
Bocchi et al. (15) 2005 d d d 6.58–6.95 d 5.8 d
Mangini et al. (17) 2008 212 55 45 10 d 8.5 d
Latado et al. (18) 2006 299 65.8 34.2 17.4 d d d
Tavares et al. (25) 2004 203 NA NA 9 and 13 d 12.6 d
Fairman et al. (19) 2009 736 60 40 8 d 7 24.5 (3 m)
Perna et al. (6) ENUC-1993 521 d 31.8–36.0 12.1–4.6 d d d
CONREC-1999 751 d 25.3–20.0 10.5–8.9 d d d
IC-SAC-2002 400 d 27 4.7 d 9.3 – 7 d
IC-SAC-2004 615 d d d d d d
CONREC-2004 687 d d d d d d
Castro et al. (11) 2004 372 69
(LVEF <40%)
NA 4.5 d 11 d
Bocchi et al. (20) 2008 182 100 d 14.8 d 8 36 (5 m)
Barretto et al. (8) 1998 903 >58.5 d 15.7 and 14.6 d d d
Rohde et al. (9) 2005 143 64 36 13 d 11 36 (3 m)
McSwain et al. (28) 1999 293 NA NA 17.4 d d d
Thierer et al. (21) 2002 400 74 25 10.5 d 7 d
Rizzo et al. (22) 2004 615 71.7 28.3 8.94 d 7 d
Thierer et al. (23) 2006 2,201 72.6 27.4 d d d d
Values are %. *Prevalence of HFPEF in the ADHERE-I (Acute Decompensated Heart Failure National Registry–International) trial; ypatients from Brazil; zpatients from Mexico.
LVEF ¼ left ventricular ejection fraction; HFPEF ¼ heart failure with preserved ejection fraction; m ¼ months; SHF ¼ systolic heart failure; other abbreviations as in Table 1.
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953and the United States: 6 days (range: 4 to 10 days) versus 4
days (range: 3 to 7 days) (24). However, in-hospital
mortality rates (unadjusted) for patients hospitalized with
HF and HFPEF showed wide variation by the country of
enrollment. The United States had the third lowest observed
inpatient mortality rate (2.7%); Brazil had the highest
(8.5%), whereas México had 2.9%, and Hong Kong had the
lowest (0.5%). Patients in the U.S. cohort presented with
more comorbidities (such as prior myocardial infarction,
renal insufﬁciency) and peripheral edema compared with
patients outside the United States. The I Latin America
Guidelines for the Assessment and Management of
Decompensated Heart Failure reported that in Brazil, the
average hospital stay was 5.8 days and in-hospital mortality
was 6.58% to 6.95% (15). Also, in a study from Brazil,
patients admitted into public hospitals were on average 1
decade younger in comparison with patients in private
hospitals (25). In this study, HF patients hospitalized in
public hospitals consisted of a higher percentage of Afro-
Brazilians (65% vs. 20% in private hospitals), illiterateindividuals (56% vs. 11% in private hospitals), and patients
who had frequently suspended medication before the
hospital admission (51% vs. 17% in private hospitals). The
length of hospitalization and the mortality rate adjusted for
age were higher in patients in the public health system.
These ﬁndings reinforce the concept of lack of access to
preventive management of HF risk factors and treatment in
socioeconomically deprived populations.
In summary, DHF is an important cause of mortality and
hospitalization in LA, mainly in the elderly population.
Length of hospitalization seems to be longer in LA, and the
mortality is heterogeneous among the countries. Hospitalized
patients in public hospitals may be younger and with fewer
comorbidities.
Systolic HF in LA
Table 2 shows the prevalence and prognosis of systolic HF
in hospitalized DHF patients and outpatients. In the
Chilean National Registry of Heart Failure, patients with
Bocchi et al. JACC Vol. 62, No. 11, 2013
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954impaired systolic function were more often men (73.7% vs.
36.3%) and more commonly had a history of coronary
artery disease (29.5% vs. 17.1%) in comparison with subjects
with HFPEF (26). With respect to HF in children, few
publications have reported treatment effects in idiopathic
dilated cardiomyopathy, and there are no epidemiological
studies (27).
HF due to long-standing SH is somewhat rare in Brazil
(7%) (8), which contrasts with the high prevalence of hyper-
tensive HF reported in Antigua (41%) and in Chile (35.2%),
which showed a high prevalence of systolic HF (11,28). In the
Chilean HF registry ICARO (Insuﬁciencia Cardíaca: Registro
y Organización), the etiology showed an interesting pattern
associated with socioeconomic status. For subjects in the low-
income tertile, a SH etiology was predominant (58.2%);
conversely, in the high-income tertile, an ischemic etiology was
far more common (34.5%) (29). In Argentina, the ischemic
etiology seems to be more common than the SH etiology,
ranging from 27.4% to 38.4% for ischemic HF versus 18.2% to
23.7% for systolic HF (30). This also seems to be the case in
Mexico and Colombia (27.5%) (31,32). Also, association of
comorbidities with HF has been reported in LA, with relevant
published data concerning diabetes mellitus, dyslipidemia,
hypothyroidism, chronic obstructive pulmonary disease, renal
dysfunction, and anemia (33,34).
Despite the advances in HF treatment, compliance with
international and national guidelines remains low in LA
(35). Furthermore, there is no substantial ﬁnancial support
for development of trials speciﬁc for the LA population, as
observed for the planned IRON-HF (Iron Supplementation
in Heart Failure Patients With Anemia) trial (36). In the
Chilean HF registry ICARO, beta-blocker use at admission
was very low (15%) and did not improve substantially at
discharge (21%). Conversely, levels of angiotensin-
converting enzyme inhibitor/angiotensin receptor antago-
nist use, although below recommendations, were acceptable
both at admission (44.5%) and at discharge (67.9%) (11).
Medical treatment at the time of admission to the emer-
gency room due to DHF showed a wide variation according
to socioeconomic status. High-income subjects were more
often adequately treated, and 44% received a beta-blocker. By
contrast, low-income subjects were usually undertreated, and
merely 23.6% were prescribed a beta-blocker (32). These
results contrast with the high rates of compliance with the
established guidelines seen in clinical trials from Argentina
and Brazil (4,37,38). Success of HF education programs,
which is dependent upon socioeconomic status, was reported
in randomized prospective trials in Brazil and Argentina (39).
The REMADHE (A Long-Term Prospective Randomized
Controlled Study Using Repetitive Education at Six-Month
Intervals and Monitoring for Adherence in Heart Failure
Outpatients) trial, developed in Brazil, was designed to
include outpatients for long-term follow-up, with repetitive
education at 6-month intervals (39). The intervention
included the education of patients and caregivers; patients
had their medical treatment optimized based on currentguidelines, and received remote monitoring. The multidis-
ciplinary team of care providers included nurses, cardiolo-
gists, pharmacists, social workers, dieticians, dentists, and
psychologists. Communication with patients and caregivers
was made during individual or group face-to-face interviews,
as well as by telephone. The interval between interviews
was reduced in the presence of any change in clinical status
that required evaluation and/or treatment modiﬁcations.
A daytime telephone number was provided to patients for
emergencies or questions about HF management (39).
For severely ill patients, heart transplantation availability
differs widely among countries. Brazil has one of the largest
transplantation programs in the world, second only to the
United States. Patients submitted for heart transplantation
in a Brazilian center were young (mean, 36 years of age), and
a large portion had dilated cardiomyopathy (53.4%) (40). In
a tertiary center in Argentina, the mean age was 46 years,
and the most common etiology for HF was ischemic (37%)
(41). Those ﬁndings are closely similar to those published by
a Chilean tertiary center, in which the mean age of the
recipient was 43 years old, and the main etiology for HF was
ischemic (40%), closely followed by dilated cardiomyopathy
(36%). Survival was 87.2% at 1 year, and 74.7% at 7 years
(42,43). Many surgical procedures have been tested in LA
for systolic HF treatment, but none of them are used in
current clinical practice (44,45). Stem cell–based treatment
was also investigated in HF (46).
In summary, systolic HF is a common syndrome in LA,
and the major etiology is heterogeneous according to each
country and is under the inﬂuence of socioeconomic status.
SH and coronary artery disease are the main etiologies. In
general, compliance with guidelines is low in clinical prac-
tice, except in some countries and selected centers. Heart
transplantation is developed in select areas.
HF Due to Neglected Diseases in LA
Chagas’ heart disease and rheumatic heart disease continue
to be a burden in LA, affecting large sectors of the pop-
ulation (Table 1). Multiple factors explain the persistence of
these neglected etiologies, such as the lower total expendi-
ture on health, the lower income of the population, and
limited funding assigned to prevention and treatment of
these diseases in LA.
C’D was responsible for 7.8% of HF deaths in a report
from Brazil (14). C’D etiology was reported in a range from
8.1% to 21% of HF outpatients, and in 0.6% to 21% of
hospitalized patients with DHF (Table 1). It is estimated
that 21,000 deaths related to C’D occur every year in Brazil,
Chile, Argentina, Paraguay, Peru, and Uruguay in LA (47).
The patients with chagasic HF are younger in comparison
with other etiologies. C’D is endemic in 21 countries in LA.
About 7 million to 8 million people worldwide are estimated
to be infected with Trypanosoma cruzi worldwide, mostly in
LA (48). Despite more countries endemically involved due
mainly to population mobility, the number of infected
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Trypanosoma cruzi, the agent responsible for the infection, is
most frequently acquired through vector-borne transmission
from triatomine bugs; however, the T. cruzi infection can
also arise through blood transfusions, congenital infection,
needle-stick injuries, oral transmission, and organ trans-
plantation (50).
Longitudinal studies show that from 25% to 30% of
infected individuals develop chronic C’D including symp-
toms related to heart damage (51). Three phases are
described in the course of the disease. In the acute phase,
which lasts between 15 and 30 days, the feature can be
intense parasitemia, which in turn triggers both B and T
lymphocyte–mediated immune responses. In this phase, the
patient can manifest a clinical status from asymptomatic to
severe systemic infection with myocarditis. The subacute or
indeterminate phase, lasting between 5 and 20 years, is
characterized by low blood parasite concentrations and
myocardial or nerve lesions generating minimal or no
symptoms, and can only be detected using ancillary diag-
nostic tests (52). Seventy percent to 80% of positive serology
patients remain in the indeterminate phase; the remaining
20% to 30% enter the chronic phase, exhibiting mainly
cardiac involvement (53), which may cause death due to
ventricular arrhythmias, conduction disorders, embolic
events, and severe HF. The detection of T. cruzi antigens in
chronic chagasic cardiomyopathy and the reported reac-
tivation of the T. cruzi infection associated with myocarditis
after heart transplantation suggest a direct effect of the agent
apart from immunological mechanisms (54). However, the
value of speciﬁc treatment for T. cruzi infection in chronic
chagasic cardiomyopathy needs to be proven in randomized
prospective trials in LA, taking into consideration the
ineffective preventive treatment of T. cruzi infection reac-
tivation in heart transplantation (55). Furthermore, coin-
fection with mycoplasma, chlamydia, virus, and archaeal
organisms has been reported, emphasizing the complexity of
chagasic cardiomyopathy (56,57). Chagasic HF is associated
with systemic inﬂammatory and neurohormonal activation
(58). However, a recent LA guidelines proposed a new
classiﬁcation of the chronic C’D in 4 stages (A, B1/B2, C,
and D), such as in HF, according to the extent of cardiac
damage, with the objective of better management of the
epidemiology, prevention, and treatment of C’D (59).
Despite the worse outcome of patients with C’D in
comparison with other etiologies having been ﬁrst published
in 1994 (60), there are no established speciﬁc trials for
pharmacological chagasic HF treatment. When only patients
using beta-blockers were considered, the survival of patients
with C’D was similar to that of other etiologies, suggesting
that beta-blockers may have a beneﬁcial effect on survival
in patients with HF and Chagas’ heart disease (61).
Consequently, research on surgical procedures and stem
cell treatment has been promoted for chagasic HF in LA
(62,63). However, sudden death, persistent myocarditis,
right ventricular dysfunction, and myocardial ﬁbrosis arejustiﬁcations for the lack of successful surgical procedures
for chagasic HF, with the exception of heart transplantation
(64–66). The common right ventricular dysfunction ob-
served in C’D could be a limitation for left ventricular assist
devices. On other hand, C’D HF may have low pulmonary
hypertension (67). Successful ventricular assist device
procedures as a bridge for heart transplantation were re-
ported (68). Heart transplantation is now accepted as the
surgical treatment of choice for chagasic refractory HF
despite the risk of T. cruzi infection reactivation (61,69).
Successful long-term survival after heart transplantation for
Chagas’ heart disease was reported (70,71). T. cruzi infection
has been reported to occur in 26.5% to 42.9% of cases
(72,73). A multivariate analysis showed rejection episodes,
neoplasms, and mycophenolate mofetil use as independent
determinants for factors (74–76). Prophylactic treatment
early after transplantation was of no beneﬁt in a small cohort
of patients (77).
Rheumatic cardiopathy is still a signiﬁcant cause of
morbidity and mortality in LA (Table 1). Rheumatic val-
vulopathy is an important indication for cardiac surgery both
in children and adults in LA (78). Reports from the
Ministry of Health in Brazil show that in that country, about
22,000 patients develop rheumatic cardiopathy every year,
and the prevalence of rheumatic fever is 3% to 5% in chil-
dren and adolescents (79). Rheumatic fever prevalence was
also reported to range from 7.9 of 1,000 inhabitants in
La Paz (Bolivia) to 2.9 of 1,000 inhabitants in Cuba (80). In
2003, 101,822 cases of rheumatic fever were reported in
children in LA. These data show that rheumatic fever and
its associated complications, characterized by valve disease
and HF, still pose a challenge to public health in LA.
In summary, C’D and rheumatic cardiopathy are impor-
tant neglected causes of HF in LA. There are no speciﬁc
trials for treatment of C’D; it is treated similarly to other
etiologies despite the different physiopathology.
HF With Preserved Ejection Fraction
In reports from LA, the prevalence of HFPEF was 0% to
37% in HF outpatients, whereas in hospitalized patients, it
was 20% to 45.7% (Table 2). SH prevalence observed in LA
subjects in the I-PREFER (Identiﬁcation of Patients With
Heart Failure and PREserved Systolic Function: an epide-
miological regional study) study (81) was greater than that
observed in patients with HFPEF in developed countries.
Also, the blood pressure control in patients with SH and
HFPEF differed according to the region. Blood pressure
was controlled in only 39% of patients in LA. The high rate
of SH, together with inadequate blood pressure control in
LA patients, could be one factor leading to HFPEF in LA.
Figure 6 shows medical treatment of HFPEF in LA.
HFPEF is common in LA; however, the prevalence may
be lower in comparison with systolic HF. The younger age
observed in HF trials in LA could be a factor inﬂuencing the
epidemiology of HFPEF in LA.
Figure 6
Medication Use Among Patients With HFPEF in
Certain LA Countries
Data are modiﬁed from the I-PREFER study (82). HFPEF ¼ heart failure with
preserved left ventricular ejection fraction; I-PREFER ¼ Identiﬁcation of Patients
With Heart Failure and PREserved Systolic Function: an epidemiological regional
study; LA ¼ Latin America.
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956Limitations
The most important limitation of this systematic review is
that data in general were obtained from registries,
government-based databases, selected populations or insti-
tutions, and trials with inherent bias. However, the data
were the best available and can be the basis for planning
well-designed future studies.
Clinical Implication and Conclusions
Despite the shortcomings of the available published data, it is
clear that there is an excess burden of systolic, HFPEF, and
DHF HF in LA leading to high rates of hospitalization and
high mortality. LA is under the awful paradox of the HF risk
factors and HF epidemiology of developed countries with an
added high prevalence of SH, C’D, and rheumatic fever,
together with a lower total expenditure on health per capita.
Lower total expenditure on health per capita in LA indicates
limited access to primary or secondary care of diseases
leading to HF. As a consequence of multiple factors in LA,
the HF population seems to be younger than in developed
countries. New strategies for prevention and treatment of
HF are essential in LA. Speciﬁc trials for LA populations are
necessary. There is a need for large-scale epidemiological
studies of the incidence, prevalence, determinants, and
outcome of HF in LA to guide strategies for the treatment
and prevention of HF in LA. Implementation of public
policies proposed in 2012 jointly by the Brazilian Society of
Cardiology, American Heart Association, European Society
of Cardiology, World Heart Federation, and Interamerican
Society of Cardiology (Letter of the Rio de Janeiro,
IIIdBrazil Prevent & I Latin America Prevent, 2012) could
reduce the HF burden in Latin America (82).Acknowledgment
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